Circassia Pharmaceuticals (LON:CIR) Earns Buy Rating from Peel Hunt

Peel Hunt reissued their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a research note released on Monday morning, ThisIsMoney.Co.Uk reports.

Separately, FinnCap assumed coverage on shares of Circassia Pharmaceuticals in a report on Thursday, September 26th. They set a corporate rating and a GBX 80 ($1.05) price target on the stock.

Shares of LON:CIR opened at GBX 16.50 ($0.22) on Monday. The company has a debt-to-equity ratio of 21.61, a current ratio of 0.40 and a quick ratio of 0.35. Circassia Pharmaceuticals has a 1-year low of GBX 13.25 ($0.17) and a 1-year high of GBX 78.20 ($1.02). The company has a market capitalization of $61.91 million and a P/E ratio of -0.49. The firm’s 50 day simple moving average is GBX 17.64 and its two-hundred day simple moving average is GBX 22.38.

In other news, insider Jonathan Emms purchased 300,000 shares of the stock in a transaction on Monday, September 30th. The shares were acquired at an average price of GBX 17 ($0.22) per share, with a total value of £51,000 ($66,640.53).

About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Featured Article: Why do earnings reports matter?

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.